Search

Your search keyword '"Seto, Wai-Kay"' showing total 1,198 results
Start Over Author "Seto, Wai-Kay"
1,198 results on '"Seto, Wai-Kay"'

101. The Hong Kong consensus recommendations on the diagnosis and management of pancreatic cystic lesions

Author

Cheung, Tan-To, primary, Lee, Yuk Tong, additional, Tang, Raymond Shing-Yan, additional, She, Wong Hoi, additional, Cheng, Kai Chi, additional, Cheung, Chin Cheung, additional, Chiu, Keith Wan Hang, additional, Chok, Kenneth Siu Ho, additional, Chow, Wing Sun, additional, Lai, Tak Wing, additional, Seto, Wai-Kay, additional, and Yau, Thomas, additional

Published
2023
Full Text
View/download PDF

111. Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease

Author

Sun, Chao, primary, Goh, George Boon-Bee, additional, Chow, Wan-Cheng, additional, Chan, Wah-Kheong, additional, Wong, Grace Lai-Hung, additional, Seto, Wai-Kay, additional, Huang, Yi-Hsiang, additional, Lin, Han-Chieh, additional, Lee, I-Cheng, additional, Lee, Hye Won, additional, Kim, Seung Up, additional, Wong, Vincent Wai-Sun, additional, and Fan, Jian-Gao, additional

Published
2023
Full Text
View/download PDF

114. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Author

Buti, Maria, Gane, Edward, Seto, Wai Kay, Chan, Henry L Y, Chuang, Wan-Long, Stepanova, Tatjana, Hui, Aric-Josun, Lim, Young-Suk, Mehta, Rajiv, Janssen, Harry L A, Acharya, Subrat K, Flaherty, John F, Massetto, Benedetta, Cathcart, Andrea L, Kim, Kyungpil, Gaggar, Anuj, Subramanian, G Mani, McHutchison, John G, Pan, Calvin Q, Brunetto, Maurizia, Izumi, Namiki, and Marcellin, Patrick

Published
2016
Full Text
View/download PDF

115. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Author

Chan, Henry L Y, Fung, Scott, Seto, Wai Kay, Chuang, Wan-Long, Chen, Chi-Yi, Kim, Hyung Joon, Hui, Aric Josun, Janssen, Harry L A, Chowdhury, Abhijit, Tsang, Tak Yin Owen, Mehta, Rajiv, Gane, Edward, Flaherty, John F, Massetto, Benedetta, Gaggar, Anuj, Kitrinos, Kathryn M, Lin, Lanjia, Subramanian, G Mani, McHutchison, John G, Lim, Young-Suk, Acharya, Subrat K, and Agarwal, Kosh

Published
2016
Full Text
View/download PDF

120. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Author

Yurdaydın, Cihan (ORCID 0000-0002-5419-7158 & YÖK ID 189330), Fung, Scott K.; Pan, Calvin Q.; Wong, Grace Lai-Hung; Seto, Wai-Kay; Ahn, Sang Hoon; Chen, Chi-Yi; Hann, Hie-Won L.; Jablkowski, Maciej S.; Kim, Yoon Jun; Peng, Cheng-Yuan; Nguyen, Tuan; Yatsuhashi, Hiroshi; Flaherty, John F.; Yee, Leland J.; Abramov, Frida; Wang, Hongyuan; Abdurakhmanov, Dzhamal; Lim, Young-Suk; Buti, Maria, School of Medicine, Yurdaydın, Cihan (ORCID 0000-0002-5419-7158 & YÖK ID 189330), Fung, Scott K.; Pan, Calvin Q.; Wong, Grace Lai-Hung; Seto, Wai-Kay; Ahn, Sang Hoon; Chen, Chi-Yi; Hann, Hie-Won L.; Jablkowski, Maciej S.; Kim, Yoon Jun; Peng, Cheng-Yuan; Nguyen, Tuan; Yatsuhashi, Hiroshi; Flaherty, John F.; Yee, Leland J.; Abramov, Frida; Wang, Hongyuan; Abdurakhmanov, Dzhamal; Lim, Young-Suk; Buti, Maria, and School of Medicine

Abstract

Background: patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles. Aim: to evaluate how these changes affect cardiovascular risk. Methods :this pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40-79 years, high-density lipoprotein [HDL] 20-100 mg/dL, total cholesterol [TC] 130-320 mg/dL and systolic blood pressure 90-200 mmHg) required to assess 10-year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post-baseline measurement were included in the ASCVD-risk population. The 10-year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate- (>= 7.5%) and high-risk (>= 20%) cut-offs. Results: among 1632 patients, 620 (38%) met the criteria for the ASCVD-risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD-risk categories during the 96-week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events. Conclusion: despite on-treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks., This work has been funded by Gilead Sciences Ltd.

Published
2023

121. Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal:Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

Author

Hirode, Grishma, Hansen, Bettina E., Chen, Chien Hung, Su, Tung Hung, Wong, Grace, Seto, Wai Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Brakenhoff, Sylvia M., Lens, Sabela, Choi, Hannah S.J., Chien, Rong Nan, Feld, Jordan J., Forns, Xavier, Sonneveld, Milan J., Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man Fung, Chan, Henry L.Y., Kao, Jia Horng, Hsu, Yao Chun, Cornberg, Markus, Jeng, Wen Juei, Janssen, Harry L.A., Hirode, Grishma, Hansen, Bettina E., Chen, Chien Hung, Su, Tung Hung, Wong, Grace, Seto, Wai Kay, Van Hees, Stijn, Papatheodoridi, Margarita, Brakenhoff, Sylvia M., Lens, Sabela, Choi, Hannah S.J., Chien, Rong Nan, Feld, Jordan J., Forns, Xavier, Sonneveld, Milan J., Papatheodoridis, George V., Vanwolleghem, Thomas, Yuen, Man Fung, Chan, Henry L.Y., Kao, Jia Horng, Hsu, Yao Chun, Cornberg, Markus, Jeng, Wen Juei, and Janssen, Harry L.A.

Abstract

INTRODUCTION: Despite improvements in the management of chronic hepatitis B (CHB), risk of cirrhosis and hepatocellular carcinoma remains. While hepatitis B surface antigen loss is the optimal end point, safe discontinuation of nucleos(t)ide analog (NA) therapy is controversial because of the possibility of severe or fatal reactivation flares.METHODS: This is a multicenter cohort study of virally suppressed, end-of-therapy (EOT) hepatitis B e antigen (HBeAg)-negative CHB patients who stopped NA therapy (n = 1,557). Survival analysis techniques were used to analyze off-therapy rates of hepatic decompensation and differences by patient characteristics. We also examined a subgroup of noncirrhotic patients with consolidation therapy of ≥12 months before cessation (n = 1,289). Hepatic decompensation was considered related to therapy cessation if diagnosed off therapy or within 6 months of starting retreatment. RESULTS: Among the total cohort (11.8% diagnosed with cirrhosis, 84.2% start-of-therapy HBeAg-negative), 20 developed hepatic decompensation after NA cessation; 10 events were among the subgroup. The cumulative incidence of hepatic decompensation at 60 months off therapy among the total cohort and subgroup was 1.8% and 1.1%, respectively. The hepatic decompensation rate was higher among patients with cirrhosis (hazard ratio [HR] 5.08, P < 0.001) and start-of-therapy HBeAg-positive patients (HR 5.23, P < 0.001). This association between start-of-therapy HBeAg status and hepatic decompensation remained significant even among the subgroup (HR 10.5, P < 0.001). DISCUSSION: Patients with cirrhosis and start-of-therapy HBeAg-positive patients should be carefully assessed before stopping NAs to prevent hepatic decompensation. Frequent monitoring of viral and host kinetics after cessation is crucial to determine patient outcome.

Published
2023

122. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B:A multicentre cohort study

Author

Sonneveld, Milan J., Chiu, Shao Ming, Park, Jun Yong, Brakenhoff, Sylvia M., Kaewdech, Apichat, Seto, Wai Kay, Tanaka, Yasuhito, Carey, Ivana, Papatheodoridi, Margarita, Colombatto, Piero, van Bömmel, Florian, Berg, Thomas, Zoulim, Fabien, Ahn, Sang Hoon, Dalekos, George N., Erler, Nicole S., Brunetto, Maurizia, Wedemeyer, Heiner, Cornberg, Markus, Yuen, Man Fung, Agarwal, Kosh, Boonstra, Andre, Buti, Maria, Piratvisuth, Teerha, Papatheodoridis, George, Chen, Chien Hung, Maasoumy, Benjamin, Sonneveld, Milan J., Chiu, Shao Ming, Park, Jun Yong, Brakenhoff, Sylvia M., Kaewdech, Apichat, Seto, Wai Kay, Tanaka, Yasuhito, Carey, Ivana, Papatheodoridi, Margarita, Colombatto, Piero, van Bömmel, Florian, Berg, Thomas, Zoulim, Fabien, Ahn, Sang Hoon, Dalekos, George N., Erler, Nicole S., Brunetto, Maurizia, Wedemeyer, Heiner, Cornberg, Markus, Yuen, Man Fung, Agarwal, Kosh, Boonstra, Andre, Buti, Maria, Piratvisuth, Teerha, Papatheodoridis, George, Chen, Chien Hung, and Maasoumy, Benjamin

Abstract

Background & Aims: Pretreatment predictors of finite nucleo(s)tide analogue (NUC) therapy remain elusive. We studied the association between pretreatment HBV DNA levels and outcomes after therapy cessation. Methods: Patients with chronic hepatitis B who were HBeAg negative at the start of NUC treatment were enrolled from sites in Asia and Europe. We studied the association between pretreatment HBV DNA levels and (1) clinical relapse (defined as HBV DNA >2,000 IU/ml + alanine aminotransferase >2 × the upper limit of normal or retreatment) and (2) HBsAg loss after NUC withdrawal. Results: We enrolled 757 patients, 88% Asian, 57% treated with entecavir, with a median duration of treatment of 159 (IQR 156–262) weeks. Mean pretreatment HBV DNA levels were 5.70 (SD 1.5) log IU/ml and were low (<20,000 IU/ml) in 150 (20%) and high (>20,000 IU/ml) in 607 (80%). The cumulative risk of clinical relapse at 144 weeks after therapy cessation was 22% among patients with pretreatment HBV DNA levels <20,000 IU/ml vs. 60% among patients with pretreatment HBV DNA levels >20,000 IU/ml, whereas the cumulative probabilities of HBsAg loss were 17.5% vs. 5% (p <0.001). In multivariable analysis, pretreatment HBV DNA levels <20,000 IU/ml were independently associated with a reduced likelihood of clinical relapse (adjusted hazard ratio 0.379, p <0.001) and with an increased chance of HBsAg loss (adjusted hazard ratio 2.872, p <0.001). Conclusions: Lower pretreatment HBV DNA levels are associated with a lower risk of clinical relapse and a higher chance of HBsAg loss after cessation of NUC therapy, independent of end-of-treatment viral antigen levels. Further studies are needed to confirm these findings in non-Asian populations. Impact and Implications: A subgroup of patients with chronic hepatitis B may not require retreatment after stopping antiviral therapy. In this study, comprising 757 patients with chronic hepatitis B from Europe and Asia, we found

Published
2023

123. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Author

Lim, Young Suk, Chan, Henry L.Y., Ahn, Sang Hoon, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry L.A., Pan, Calvin Q., Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Shalimar, Brunetto, Maurizia, Hui, Aric Josun, Chang, Ting Tsung, Lim, Seng Gee, Abramov, Frida, Flaherty, John F., Wang, Hongyuan, Yee, Leland J., Kao, Jia Horng, Gane, Edward, Hou, Jinlin, Buti, Maria, Lim, Young Suk, Chan, Henry L.Y., Ahn, Sang Hoon, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry L.A., Pan, Calvin Q., Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Shalimar, Brunetto, Maurizia, Hui, Aric Josun, Chang, Ting Tsung, Lim, Seng Gee, Abramov, Frida, Flaherty, John F., Wang, Hongyuan, Yee, Leland J., Kao, Jia Horng, Gane, Edward, Hou, Jinlin, and Buti, Maria

Abstract

Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB. Methods: The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated. Results: Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p <0.001) vs. 0.56 (p = 0.06). In the general study population, individuals without cirrhosis at baseline had an SIR that was lower compared to the SIR of individuals with cirrhosis at baseline: 0.37 (p <0.001) vs. 0.58 (p = 0.15). Of the patients at low risk of HCC at baseline, the majority (97%) remained low risk by mPAGE-B and aMAP scoring at Week 240. Among those at medium or high risk at baseline, substantial portions shifted to a lower risk category by Week 240 (mPAGE-B: 22% and 42%; aMAP: 39% and 63%, respectively). Conclusions: This evaluation provides evidence that treatment with TAF or TDF can reduce HCC risk in patients with CHB, particularly in patients without cirrhosis. Impact and implications: Despite the substantial impact of HCC on long-term outcomes of patients with CHB, the differential risk of HCC development among those receiving treatment with

Published
2023

124. Portable electrical impedance tomography (EIT) system stages non-alcoholic fatty liver disease for potential screening and monitoring at home

Author

Li, Ho Wa, Touboul, Adrien, Zouari, Fedi, Cheung, Pak To, Wei, Ellie, Wong, Eddie C., Zhou, Iris Y., Yuen, Man-Fung, Seto, Wai-Kay, Mak, Lung-Yi, Chan, Russell W., Li, Ho Wa, Touboul, Adrien, Zouari, Fedi, Cheung, Pak To, Wei, Ellie, Wong, Eddie C., Zhou, Iris Y., Yuen, Man-Fung, Seto, Wai-Kay, Mak, Lung-Yi, and Chan, Russell W.

Abstract

This study demonstrates the feasibility of predicting NAFLD using multi-spectral electrical impedance tomography (EIT), group source separation, constant reference EIT and anthropometric measures. Vibration-controlled Transient Elastography (VCTE) Controlled Attenuated Parameter (CAP; n = 121) and magnetic resonance imaging-proton density fat fraction (MRI-PDFF; n = 34) achieved a sensitivity of 70.9% and specificity of 73.8% with our CAP predicting model and sensitivity of 77.8% and specificity of 80.0% with our MRI-PDFF predicting model. In summary, a portable EIT can be a cost-effective and self-administrable alternative for widespread home-based and community-based diagnostic screening and treatment monitoring of NAFLD.Clinical Relevance - Portable multi-spectral EIT system has the sensitivity and specificity to potentially unlock biomedical imaging in telemedicine for home-based and community-based screening, staging and monitoring for NAFLD. © 2023 IEEE.

Published
2023

125. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.

Author

Fung, Scott K., Pan, Calvin Q., Wong, Grace Lai‐Hung, Seto, Wai‐Kay, Ahn, Sang Hoon, Chen, Chi‐Yi, Hann, Hie‐Won L., Jablkowski, Maciej S., Kim, Yoon Jun, Yurdaydin, Cihan, Peng, Cheng‐Yuan, Nguyen, Tuan, Yatsuhashi, Hiroshi, Flaherty, John F., Yee, Leland J., Abramov, Frida, Wang, Hongyuan, Abdurakhmanov, Dzhamal, Lim, Young‐Suk, and Buti, Maria

Subjects
CHRONIC hepatitis B, CARDIOVASCULAR diseases risk factors, CARDIOVASCULAR diseases, TENOFOVIR, SYSTOLIC blood pressure
Abstract

Summary: Background: Patients with chronic hepatitis B (CHB) who switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) show changes in lipid profiles. Aim: To evaluate how these changes affect cardiovascular risk. Methods: This pooled analysis, based on two large prospective studies, evaluated fasting lipid profiles of patients with CHB who were treated with TAF 25 mg/day or TDF 300 mg/day for 96 weeks. Patients who fulfilled the American College of Cardiology criteria (age 40–79 years, high‐density lipoprotein [HDL] 20–100 mg/dL, total cholesterol [TC] 130–320 mg/dL and systolic blood pressure 90–200 mmHg) required to assess 10‐year atherosclerotic cardiovascular disease (ASCVD) risk with baseline lipid data and at least one post‐baseline measurement were included in the ASCVD‐risk population. The 10‐year ASCVD risk was calculated for patients in this population, and changes from baseline to Week 96 were assessed using intermediate‐ (≥7.5%) and high‐risk (≥20%) cut‐offs. Results: Among 1632 patients, 620 (38%) met the criteria for the ASCVD‐risk population. At Week 96, fasting levels of all lipids, except TC:HDL ratio, were lower with TDF than TAF. No significant increase was observed in overall ASCVD risk or in any ASCVD‐risk categories during the 96‐week treatment period compared with baseline. A similar proportion of patients in the TAF and TDF treatment groups (1.3% and 2.3%, respectively; p = 0.34) reported cardiovascular events. Conclusion: Despite on‐treatment differences in lipid profiles with TAF and TDF, predicted cardiovascular risk and clinical events were similar for both groups after 96 weeks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

126. Plasma interferon‐gamma‐inducible‐protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients.

Author

Kan, Karin, Wong, Danny Ka‐Ho, Hui, Rex Wan‐Hin, Seto, Wai Kay, Yuen, Man‐Fung, and Mak, Lung‐Yi

Subjects
HEPATITIS associated antigen, CHRONIC hepatitis B, RECEIVER operating characteristic curves, HEPATITIS B virus
Abstract

Background and Aim: Spontaneous seroclearance of hepatitis B surface antigen (HBsAg) is a rare event that occurs in patients that are chronically infected with the hepatitis B virus. As the functional cure and ultimate treatment endpoint of chronic hepatitis B (CHB), HBsAg seroclearance is an important milestone in the natural history of CHB and serves great clinical value. This study aims to identify host and viral factors associated with HBsAg seroclearance. Methods: This is a retrospective study carried out in the Queen Mary Hospital, Hong Kong. By analyzing the plasma retrieved from the serum archive (collected during 2011–2021) of 100 CHB patients attending the hospital's liver clinic, the longitudinal cytokine profiles between the HBsAg‐losers and the control groups were compared. Results: Data revealed that plasma levels of IP‐10 were significantly lower at 3–5 years prior to HBsAg seroclearance compared with patients who remained HBsAg positive (P < 0.05). Receiver operating characteristic curve analysis reveals that plasma IP‐10 levels at multiple time points before HBsAg seroclearance return area under receivor‐operating characteristic curve (AUC) greater than 0.7. Plasma IP‐10 levels at 42.39 pg/mL produced an AUC = 0.723 with 74.0% sensitivity and 75.5% specificity to predict subsequent HBsAg seroclearance in the next 3–5 years. Low plasma IP‐10 identified 91.4% patients with quantitative HBsAg < 100 IU/mL who would subsequently develop HBsAg seroclearance, compared with 37% with higher plasma IP‐10 levels (P < 0.001). Conclusions: Low plasma levels of IP‐10 are associated with subsequent HBsAg seroclearance, suggesting potential clinical utilities of measurement of IP‐10 in predicting HBsAg seroclearance, especially among patients with low HBsAg. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

128. Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study)

Author

Dongelmans, Edo, primary, Hirode, Grishma, additional, Hansen, Bettina, additional, Chen, Chien-Hung, additional, Su, Tung-Hung, additional, Seto, Wai-Kay, additional, d’Almeida, Arno Furquim, additional, Van Hees, Stijn, additional, Papatheodoridi, Margarita, additional, Lens, Sabela, additional, Wong, Grace, additional, Brakenhoff, Sylvia, additional, Chien, Rong-Nan, additional, Feld, Jordan J., additional, Chan, Henry Ly, additional, Forns, Xavier, additional, Papatheodoridis, George, additional, Vanwolleghem, Thomas, additional, Yuen, Man-Fung, additional, Hsu, Yao-Chun (Holden), additional, Kao, Jia-Horng, additional, Cornberg, Markus, additional, Sonneveld, Milan, additional, Jeng, Rachel Wen-Juei, additional, and Janssen, Harry LA, additional

Published
2023
Full Text
View/download PDF

129. Glycemic control as a modifiable and independent risk factor for the development of liver, biliary tract and pancreatic cancer: a territory-wide study of 273,421 patients with diabetes mellitus

Author

Mao, Xianhua, primary, Cheung, Ka Shing, additional, Tan, Jing Tong, additional, Mak, Lung-Yi, additional, Lee, Chi Ho, additional, Chiang, CL, additional, Cheng, Ho Ming, additional, Hui, Rex Wan-Hin, additional, Yuen, Man-Fung, additional, Leung, Wai Keung, additional, and Seto, Wai-Kay, additional

Published
2023
Full Text
View/download PDF

130. Utility of partial cure as an end point after nucleos (t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study)

Author

Hirode, Grishma, primary, Hansen, Bettina, additional, Chen, Chien-Hung, additional, Su, Tung-Hung, additional, Wong, Grace, additional, Seto, Wai-Kay, additional, d’Almeida, Arno Furquim, additional, Papatheodoridi, Margarita, additional, Brakenhoff, Sylvia, additional, Lens, Sabela, additional, Choi, Hannah S.J., additional, Van Hees, Stijn, additional, Chien, Rong-Nan, additional, Feld, Jordan J., additional, Forns, Xavier, additional, Sonneveld, Milan, additional, Papatheodoridis, George, additional, Vanwolleghem, Thomas, additional, Yuen, Man-Fung, additional, Chan, Henry LY, additional, Kao, Jia-Horng, additional, Hsu, Yao-Chun (Holden), additional, Cornberg, Markus, additional, Jeng, Rachel Wen-Juei, additional, and Janssen, Harry LA, additional

Published
2023
Full Text
View/download PDF

131. Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy

Author

Sonneveld, Milan, primary, Chiu, SM, additional, Park, Jun Yong, additional, Brakenhoff, Sylvia, additional, Kaewdech, A, additional, Seto, Wai-Kay, additional, Tanaka, Yasuhito, additional, Carey, Ivana, additional, Papatheodoridi, Margarita, additional, Colombatto, Piero, additional, van Bömmel, Florian, additional, Berg, Thomas, additional, Zoulim, Fabien, additional, Ahn, Sang Hoon, additional, Dalekos, George, additional, Erler, Nicole, additional, Brunetto, Maurizia, additional, Wedemeyer, Heiner, additional, Cornberg, Markus, additional, Yuen, Man-Fung, additional, Agarwal, Kosh, additional, Boonstra, Andre, additional, Buti, Maria, additional, Piratvisuth, Teerha, additional, Papatheodoridis, George, additional, Chen, Chien-Hung, additional, and Maasoumy, Benjamin, additional

Published
2023
Full Text
View/download PDF

133. Deep learning-based model in pre-operative computed tomography for prediction of hepatocellular carcinoma recurrence after curative surgery

Author

Hui, Rex Wan-Hin, primary, Hang Chiu, Keith Wan, additional, Lee, I-Cheng, additional, Wang, Chenlu, additional, Cheng, Ho Ming, additional, Lam, Lok-Ka, additional, Loey Mak, Lung Yi, additional, Chia, Nam-Hung, additional, Cheung, Chin-Cheung, additional, Huang, Yi-Hsiang, additional, Yuen, Man-Fung, additional, Yu, Philip, additional, and Seto, Wai-Kay, additional

Published
2023
Full Text
View/download PDF

134. Wearable technology utilizing an electrical impedance tomography (EIT) system for hepatic steatosis quantification and the role in ambulatory monitoring

Author

Loey Mak, Lung Yi, primary, Li, James H.W., additional, Touboul, Adrien, additional, Zouari, Fedi, additional, Cheung, Pak-To, additional, Wong, Eddie, additional, Zhou, Iris Y., additional, Wei, Ellie, additional, Yuen, Man-Fung, additional, Chan, Russell, additional, and Seto, Wai-Kay, additional

Published
2023
Full Text
View/download PDF

135. Nosocomial infections in cirrhosis are unpredictable and vary based on region of the world: CLEARED study

Author

Bajaj, Jasmohan S, primary, Wong, Florence, additional, Xie, Qing, additional, Kamath, Patrick S., additional, Topazian, Mark, additional, Sarin, Shiv Kumar, additional, Kumar, Shiva, additional, Marciano, Sebastián, additional, Tudehope, Fiona, additional, Gibson, Robert, additional, Doyle, Adam, additional, Riordan, Stephen, additional, Farias, Alberto Queiroz, additional, Faisal, Nabiha, additional, Tandon, Puneeta, additional, Lohoues, Marie Jeanne, additional, Benitez, Carlos, additional, Xian, Yongchao, additional, Zhu, Chuanwu, additional, Su, Minghua, additional, Jiang, Yongfang, additional, Zhao, Caiyan, additional, Wang, Lei, additional, Lu, Mingqin, additional, Zhang, Ning-Ping, additional, Li, Hai, additional, Zheng, Xin, additional, Tang, Hong, additional, Xu, Bin, additional, gao, zhiliang, additional, Lin, minghua, additional, Chen, Jinjun, additional, Liu, ChengHai, additional, Hu, Peng, additional, Allah, Belimi Hibat, additional, Fisseha, Henok, additional, Aravinthan, Aloysious, additional, Rajoriya, Neil, additional, Leith, Damien, additional, Adebayo, Danielle, additional, Yung, Diana, additional, Seto, Wai-Kay, additional, Katchman, Helena, additional, Nagral, Abha, additional, Kulkarni, Anand, additional, Eapen, CE, additional, Duseja, Ajay Kumar, additional, Saraya, Anoop, additional, Rela, Mohd., additional, Anora, Anil, additional, Dhiman, Radha Krishan, additional, Anand, Anil Chandra, additional, González-Huezo, Maria Sarai, additional, Perez Hernandez, Jose Luis, additional, Zazueta, Godolfino Miranda, additional, Castillo, Mauricio, additional, Velazquez, René Malé, additional, Velarde-Ruiz Velasco, Jose Antonio, additional, Cordova, Jacqueline, additional, Bhavani, Ruveena, additional, Okeke, Edith, additional, Allam, Dalia, additional, Tan, Hiang Keat, additional, Treeprasertsuk, Sombat, additional, Haktaniyan, Busra, additional, Gunduz, Feyza, additional, Yıldırım, Abdullah Emre, additional, Karasu, Zeki, additional, Ucbilek, Enver, additional, Adanir, Haydar, additional, Albhaisi, Somaya, additional, Asrani, Sumeet, additional, Reddy, K. Rajender, additional, Shaw, Jawaid, additional, Vargas, Hugo, additional, Biggins, Scott, additional, Thuluvath, Paul J., additional, Keaveny, Andrew, additional, Hayes, Peter, additional, Torre, Aldo, additional, Idilman, Ramazan, additional, Cao, Zhujun, additional, Álvares-da-Silva, Mario, additional, George, Jacob, additional, Desalegn, Hailemichael, additional, Bush, Brian, additional, Thacker, Leroy, additional, Andres, Duarte Rojo, additional, and Choudhury, Ashok, additional

Published
2023
Full Text
View/download PDF

137. Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): A nationwide cohort study

Author

Zhang, Wenhui, primary, Huang, Yifei, additional, Xiang, Huiling, additional, Zhang, LiYao, additional, Yuan, Lili, additional, Wang, Xing, additional, Dang, Tong, additional, Zhang, Guo, additional, Hu, Shengjuan, additional, Liu, Chuan, additional, Zhang, Xiuping, additional, Peng, Lijun, additional, Gao, Min, additional, Xia, Dongli, additional, Li, Jia, additional, Song, Ying, additional, Zhou, Xiqiao, additional, Qi, Xingsi, additional, Zeng, Jing, additional, Tan, Xiaoyan, additional, Deng, Mingming, additional, Fang, Haiming, additional, Qi, Shenglin, additional, He, Song, additional, He, Yongfeng, additional, Ye, Bin, additional, Wu, Wei, additional, Shao, Jiangbo, additional, Wei, Wei, additional, Hu, Jianping, additional, Yong, Xin, additional, He, Chaohui, additional, Bao, Jinlun, additional, Zhang, Yuening, additional, Ji, Rui, additional, Bo, Yang, additional, Yan, Wei, additional, Li, Hongjiang, additional, Wang, Yong, additional, Wang, Yanling, additional, Li, Mengmeng, additional, Lian, Jia, additional, Liu, Chang’en, additional, Wu, Yunhai, additional, Gu, Ye, additional, Wang, Yan, additional, Cao, Ping, additional, Wu, Bin, additional, Ren, Limei, additional, Pan, Hongduo, additional, Liang, Yunxiao, additional, Tian, Shuni, additional, Lu, Lin, additional, Fang, Yanfei, additional, Jiang, Pan, additional, Liu, Zhenbei, additional, Liu, Aimin, additional, Zhao, Lili, additional, Li, Shuang, additional, Qiao, Jinggui, additional, Sun, Lihui, additional, Li, Mengyu, additional, Fang, Chengwen, additional, Chen, Hao, additional, Tian, Zibin, additional, Lin, Gaoyang, additional, Huang, Xuanhui, additional, Chen, Jitao, additional, Deng, Ying, additional, Lv, Muhan, additional, Liao, Jingyuan, additional, Zhang, Lijiu, additional, Lu, Junyu, additional, Wu, Suhua, additional, Yang, Xiaocui, additional, Guo, Wenwei, additional, Wang, Jianbo, additional, Chen, Chao, additional, Huang, Erjiong, additional, Yu, Yuehua, additional, Yang, Ming, additional, Cheng, Shuangping, additional, Yang, Yang, additional, Wu, Xiaoli, additional, Rang, Limaocai, additional, Han, Ping, additional, Zhang, Yanmin, additional, Li, Xiaoguo, additional, Wang, Fengmei, additional, McAlindon, Mark Edward, additional, Seto, Wai-Kay, additional, Lv, Chuanzhu, additional, Rockey, Don C., additional, and Qi, Xiaolong, additional

Published
2023
Full Text
View/download PDF

138. Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium

Author

Bajaj, Jasmohan S, primary, Choudhury, Ashok K, additional, Xie, Qing, additional, Kamath, Patrick S, additional, Topazian, Mark, additional, Hayes, Peter C, additional, Torre, Aldo, additional, Desalegn, Hailemichael, additional, Idilman, Ramazan, additional, Cao, Zhujun, additional, Alvares-da-Silva, Mario R, additional, George, Jacob, additional, Bush, Brian J, additional, Thacker, Leroy R, additional, Wong, Florence, additional, Sarin, Shiv K, additional, Kumar, Shiva, additional, Marciano, Sebastián, additional, Gadano, Adrián, additional, Tudehope, Fiona, additional, Gibson, Robert, additional, Prudence, Alexander, additional, Doyle, Adam, additional, Si, Hooi Ling, additional, Riordan, Stephen, additional, Farias, Alberto, additional, Zitelli, Patricia, additional, Bera, Chinmay, additional, Faisal, Nabiha, additional, Tandon, Puneeta, additional, Dahiya, Monica, additional, Lohoues, Marie Jeanne, additional, Lah, Ponan Claude Regis, additional, Benítez, Carlos, additional, Arrese, Marco, additional, Xian, Yongchao, additional, Guan, Jin, additional, Zhu, Chuanwu, additional, Wang, Yingling, additional, Su, Minghua, additional, Su, Man, additional, Gao, Yanhang, additional, Wang, Xinrui, additional, Jiang, Yongfang, additional, Peng, Feng, additional, Zhao, Caiyan, additional, Wang, Wei, additional, Wang, Lei, additional, Yin, Dedong, additional, Lu, Mingqin, additional, Cai, Yijing, additional, Zhang, Ningping, additional, Zhang, Wanqin, additional, Li, Hai, additional, Dong, Fuchen, additional, Zheng, Xin, additional, Liu, Jing, additional, Tang, Hong, additional, Yan, Libo, additional, Xu, Bin, additional, Wei, Linlin, additional, Gao, Zhiliang, additional, Xu, Zhen, additional, Lin, Minghua, additional, Gao, Haibin, additional, Chen, Jinjun, additional, Li, Beiling, additional, Liu, Chenghai, additional, Zhang, Yanyun, additional, Hu, Peng, additional, Deng, Huan, additional, Belimi, Hibat Allah, additional, Debzi, Nabil, additional, Fisseha, Henok, additional, Aravinthan, Aloysious D, additional, Venkatachalapathy, Suresh Vasan, additional, Rajoriya, Neil, additional, Faulkes, Rosemary, additional, Leith, Damien, additional, Forrest, Ewan, additional, Adebayo, Danielle, additional, Kennedy, James, additional, Yung, Diana, additional, Seto, Wai-Kay, additional, Fung, James, additional, Katchman, Helena, additional, Rabinowich, Liane, additional, Nagral, Aabha, additional, Jhaveri, Ajay, additional, Kulkarni, Anand, additional, Sharma, Mithun, additional, Eapen, C E, additional, Goel, Ashish, additional, Gandotra, Akash, additional, Duseja, Ajay, additional, Saraya, Anoop, additional, Yegurla, Jatin, additional, Rela, Mohamed, additional, Jothimani, Dinesh, additional, Arora, Anil, additional, Kumar, Ashish, additional, Dhiman, Radha Krishan, additional, Roy, Akash, additional, Anand, Anil C, additional, Praharaj, Dibyalochan, additional, Hueso, Sarai Gonzalez, additional, Cabrera, Araceli Bravo, additional, Pérez Hérnandez, José Luis, additional, Gutierrez, Oscar Morales, additional, Miranda Zazueta, Godolfino, additional, Ramos-Pineda, Abraham, additional, Castillo Barradas, Mauricio, additional, Velazquez, Rene Male, additional, Made, Lilian Torres, additional, Velarde-Ruiz Velasco, José Antonio, additional, Félix-Tellez, Francisco, additional, Cordova-Gallardo, Jacqueline, additional, Rajaram, Ruveena, additional, Nik Muhamad Afendi, Nik Arsyad, additional, Okeke, Edith N, additional, Nyam, David P, additional, Allam, Dalia, additional, Kumar Patwa, Yashwi Haresh, additional, Tan, Hiang Keat, additional, Liou, Wei Lun, additional, Treeprasertsuk, Sombat, additional, Wejnaruemarn, Salisa, additional, Haktaniyan, Busra, additional, Gunduz, Feyza, additional, Aslan, Rahmi, additional, Yildirim, Abdullah Emre, additional, Barutcu, Sezgin, additional, Karasu, Zeki, additional, Uysal, Alper, additional, Ucbilek, Enver, additional, Kosay, Tolga, additional, Adanir, Haydar, additional, Dinçer, Dinç, additional, Albhaisi, Somaya, additional, Asrani, Sumeet, additional, Fallahadeh, Mohammad Amin, additional, Reddy, K Rajender, additional, Rahematpura, Suditi, additional, Shaw, Jawaid, additional, Vargas, Hugo E., additional, Bayne, David, additional, Biggins, Scott W, additional, Filipek, Natalia, additional, Thuluvath, Paul, additional, Sheshadri, Somya, additional, Keaveny, Andrew, additional, Duarte Rojo, Andres, additional, and Cabello Negrillo, Ricardo, additional

Published
2023
Full Text
View/download PDF

139. Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis

Author

Mao, Xianhua, primary, Cheung, Ka Shing, additional, Peng, Chengzhi, additional, Mak, Lung‐Yi, additional, Cheng, Ho Ming, additional, Fung, James, additional, Peleg, Noam, additional, Leung, Howard H.‐W., additional, Kumar, Rajneesh, additional, Lee, Jeong‐Hoon, additional, Shlomai, Amir, additional, Yuen, Man‐Fung, additional, and Seto, Wai‐Kay, additional

Published
2023
Full Text
View/download PDF

142. Joint statement in support of hepatitis C human challenge studies

Author

Aghemo, Alessio, Akiyama, Matthew, Ali, Mohammad, Alter, Harvey, Bader, Ralf, Bailey, Justin R., Balaban, Yasemin, Banerjee, Sayantan, Barnes, Eleanor, Bartenschlager, Ralf, Baumert, Thomas F., Berenguer, Marina, Bhadoria, Ajeet S., Biondi, Mia, Bonanni, Paolo, Bonella, Alcino E., Bruggmann, Philip, Bruneau, Julie, Bull, Rowena A., Butsashvili, Maia, Cahn, Pedro, Caplan, Arthur L., Chappell, Richard Y., Chisari, Francis, Chung, Ray, Cooke, Graham, Cox, Andrea L., Dalgard, Olav, Dao, Doan Y., Darzi, Ara, Dieterich, Douglas, Dillon, John F., Dore, Gregory J., Doyle, Joseph S., Drummer, Heidi E., Durbin, Anna P., Dusheiko, Geoffrey, Eberts, Jake D., Eyal, Nir, Feld, Jordan, Ferguson, Kyle, Flisiak, Robert, Forns, Xavier, Foster, Graham R., Foung, Steven, Gal-Tanamy, Meital, Gane, Ed, Gehring, Adam J., George, Jacob, Ghany, Marc G., Gilbert, Daniel T., Glaze, Kimberly, Goodman, Kenneth W., Grebely, Jason, Hamid, Saeed, Haybron, Daniel M., Holton, Richard, Ignarro, Louis J., Jackson, Tamika, Jamieson, Dale, Jollimore, Jody, Karaba, Andrew, Klein, Marina, Lauer, Georg, Law, Mansun, Lemon, Stanley M., Liang, T. Jake, Liu, Lin, Lohmann, Volker, Mak, Lung-Yi, Marinho, Rui T., Marsh, Abigail A., Miller, Lesley, Morrison, Joshua, Negro, Francesco, Nguyen, Bao-Vuong, Page, Kimberly, Paterson, Kerry, Pedrana, Alisa, Pietschmann, Thomas, Pinker, Steven, Plotkin, Stanley, Ray, Stuart C., Reau, Nancy, Remak, William M., Rice, Charles M., Ridruejo, Ezequiel, Roberts, Richard J., Roth, Alvin, Rouphael, Nadine, Sanders, Rogier, Sandvold, Russell, Schafer, Arthur, Schinkel, Janke, Seto, Wai-Kay, Shoukry, Naglaa, Singer, Peter, Solomon, Sunil, Somerville, Chris, Sonderup, Mark W., Sulkowski, Mark, Talaat, Kawsar, Temkin, Larry, Terrault, Norah, Thio, Chloe, Thomas, David L., Thompson, Alexander J., Tzarum, Netanel, van der Valk, Marc, Van Gennip, Jennifer, Waked, Imam, Walen, Alec, Walker, Christopher M., Wedemeyer, Heiner, Weijer, Charles, Wikler, Dan, Wilkinson, Dominic, Youngs, Heather, Yuen, Man-fung, Zack, Barry, Zinger, Ekaterina, Alter, Harvey J, Biondi, Mia J, Cox, Andrea L, Eberts, Jake D, Feld, Jordan J, Liang, T Jake, Morrison, Josh, Rice, Charles M, Shoukry, Naglaa H, and Thomas, David L

Published
2023
Full Text
View/download PDF

147. P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS

Author

Seto, Wai Kay, primary, Chang, Ting-Tsung, additional, Chowdhry, Abhijit, additional, Chen, Chi-Yi, additional, Celen, Mustafa Kemal, additional, Ma, Xiaoli, additional, Ma, Mang, additional, Duseja, Ajay, additional, Yoon, Ki Tae, additional, Chow, Wan Cheng, additional, Yee, Leland, additional, Weber, Gregor, additional, Youn, Ms Jin, additional, Flaherty, John F., additional, Gaggar, Anuj, additional, Gao, Bing, additional, Camus, Gregory, additional, Bassetti, Eric, additional, Hwang, Jae Seok, additional, Inokuma, Tetshuro, additional, Lin, Young- Suk, additional, and Gane, Edward J., additional

Published
2023
Full Text
View/download PDF

149. Incidence of hepatic decompensation after nucleos(t)ide analogue withdrawal: Results from a large, international, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)

Author

Hirode, Author(s): Grishma, primary, Hansen, Bettina E., additional, Chen, Chien-Hung, additional, Su, Tung-Hung, additional, Wong, Grace, additional, Seto, Wai-Kay, additional, Van Hees, Stijn, additional, Papatheodoridi, Margarita, additional, Brakenhoff, Sylvia M., additional, Lens, Sabela, additional, Choi, Hannah SJ, additional, Chien, Rong-Nan, additional, Feld, Jordan J., additional, Forns, Xavier, additional, Sonneveld, Milan J., additional, Papatheodoridis, George V., additional, Vanwolleghem, Thomas, additional, Yuen, Man-Fung, additional, Chan, Henry L. Y., additional, Kao, Jia-Horng, additional, Hsu, Yao-Chun, additional, Cornberg, Markus, additional, Jeng, Wen-Juei, additional, and Janssen, Harry L.A., additional

Published
2023
Full Text
View/download PDF

150. Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Author

Leow, Yong‐Wen, primary, Chan, Wah‐Kheong, additional, Goh, George Boon‐Bee, additional, Wong, Vincent Wai‐Sun, additional, Fan, Jian Gao, additional, Kim, Young Seok, additional, Kim, Seung Up, additional, Nakajima, Atsushi, additional, Seto, Wai‐Kay, additional, Lee, I‐Cheng, additional, Huang, Yi‐Hsiang, additional, Kim, Yoon Jun, additional, Young, Jang Jae, additional, and Chow, Wan Cheng, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results